One-year findings from the REAL5 trial show a continued growth response with use of long-acting human growth hormone treatment with somapacitan at a dose of 0.24 mg/kg per week in children born small for gestational age.
Central congenital hypothyroidism is frequently missed in Israeli infants despite a newborn screening programme for thyroid dysfunction, shows research published in the Journal of Clinical Endocrinology & Metabolism.
Dutch research indicates that health-related quality of life remains largely stable over the 12 years after completion of growth hormone therapy for short stature in children who were born small for gestational age.
Genetic testing can lead to a diagnosis in around three quarters of children with short stature from consanguineous families, suggests a study of Turkish patients.
A whole-exome sequencing study has identified novel genes involved in the development of spontaneous congenital hypopituitarism in a large group of unrelated children from Argentina.
Phase 2 trial results support use of the melanocortin-4 receptor agonist setmelanotide for the treatment of rapid excess weight gain and hunger in patients with hypothalamic obesity.
Vosoritide treatment appears to increase growth velocity in children with hypochondroplasia and is well tolerated, show study findings
Patients with adamantinomatous craniopharyngioma can be grouped into two distinct clusters based on their DNA methylation profile, Brazilian researchers report.
We are delighted to announce the upcoming Springer Healthcare IME Symposium, entitled Insights into MAnaging Growth for Endocrine Nurses (IMAGE). This meeting will take place on the 21–22 March 2024 at the Westminster Hotel and Spa, Nice, France.
The Guideline Development Group has created a set of UK guidelines to aid clinicians in the diagnosis and treatment of children and young people with adamantinomatous craniopharyngiomas.
